The term MOBKL1B Inhibitors refers to a chemical class designed to selectively modulate the activity of the MOB kinase activator 1B (MOBKL1B) protein. MOBKL1B is a member of the MOB kinase activator family, and these proteins are implicated in various cellular processes, including cell proliferation, survival, and regulation of the cell cycle. Inhibitors targeting MOBKL1B likely operate by interfering with its normal functions, disrupting the intricate molecular interactions and signaling pathways in which MOBKL1B is engaged. This interference may lead to alterations in cell cycle progression and impact cellular processes regulated by MOBKL1B.
The mechanism of action for MOBKL1B inhibitors involves their selective binding to MOBKL1B, modulating its activity and potentially influencing downstream cellular pathways. These inhibitors serve as valuable tools for researchers seeking to elucidate the specific functions of MOBKL1B within the broader context of cellular biology. The study of MOBKL1B inhibitors, in this theoretical scenario, contributes to our understanding of the regulatory mechanisms that govern cell cycle progression, offering insights into the intricate molecular processes involved in cellular proliferation and survival. As part of ongoing scientific inquiry, the exploration of MOBKL1B inhibitors adds to the broader knowledge of cellular signaling pathways and aids in uncovering potential targets for further research in cell biology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Sirolimus is an mTOR inhibitor and may downregulate MOBKL1B expression indirectly by modulating pathways that intersect with the Hippo pathway. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Doxorubicin is a DNA intercalating agent that can disrupt transcription processes, potentially leading to decreased MOBKL1B expression. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
5-Fluorouracil inhibits thymidylate synthase, which could lead to DNA damage and possibly reduce MOBKL1B expression as part of a stress response. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor and might alter gene expression profiles, including that of MOBKL1B. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets multiple kinases and might indirectly affect MOBKL1B expression through its action on related signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor and may disrupt upstream signals that influence MOBKL1B expression levels. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK, part of the MAPK pathway, which could intersect with regulatory elements controlling MOBKL1B expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, and by modulating JNK activity, it could theoretically influence MOBKL1B expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that could affect MOBKL1B expression by altering PI3K/Akt signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an ERK inhibitor which may impact MOBKL1B expression by modulating the MAPK/ERK pathway. | ||||||